CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that it
will issue a news release at 8:00 a.m. Eastern time on Wednesday,
December 11, 2013 announcing top-line results of its global Phase 2b
clinical trial comparing the company’s aldoxorubicin as a first-line
treatment for advanced soft tissue sarcomas (STS) versus the widely used
chemotherapeutic agent doxorubicin. The company will host a conference
call beginning at 10:30 a.m. Eastern time December 11 to discuss those
results and answer questions.
To access the conference call, please dial 888-463-4383 (U.S. and
Canada) or 706-679-5355 (international callers). A webcast will be
available in the investor relations section of the company’s website, www.cytrx.com.
A replay of the call and webcast will begin approximately two hours
after the live call has ended. To access the replay, dial 855-859-2056
(U.S. and Canada) or 404-537-3406 (international callers) and enter the
conference ID number: 19821609.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development
company specializing in oncology. CytRx currently is focused on the
clinical development of aldoxorubicin (formerly known as INNO-206), its
improved version of the widely used chemotherapeutic agent doxorubicin.
CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin
as a treatment for soft tissue sarcomas, has completed its Phase 1b/2
clinical trial primarily in the same indication and a Phase 1b study of
aldoxorubicin in combination with doxorubicin in patients with advanced
solid tumors, and has completed a Phase 1b pharmacokinetics clinical
trial in patients with metastatic solid tumors. CytRx plans to initiate
under a special protocol assessment a potential pivotal Phase 3 global
trial with aldoxorubicin as a therapy for patients with soft tissue
sarcomas whose tumors have progressed following treatment with
chemotherapy. CytRx has initiated a Phase 2 clinical trial with
aldoxorubicin in patients with late-stage glioblastoma (brain cancer)
and plans to initiate a Phase 2 clinical trial with aldoxorubicin in
AIDS-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of
oncology candidates based on a linker platform technology that can be
utilized with multiple chemotherapeutic agents and may allow for greater
concentration of drug at tumor sites. CytRx also has rights to two
additional drug candidates, tamibarotene and bafetinib. CytRx completed
its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in
high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek
a partner for further development of bafetinib. For more information
about CytRx Corporation, visit www.cytrx.com.
Copyright Business Wire 2013